MedTrace Logo

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00636636 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2012-02-22

Study results available
· View outcomes & findings →

Summary

Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.

Conditions

  • Neuralgia,Postherpetic

Interventions

DRUG

Gabapentin Extended Release tablets

Once-Daily; 300 mg and 600 mg tablets

DRUG

Placebo

Once daily; 300 mg and 600 mg tablets

Sponsors & Collaborators

  • Depomed

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States
  • Argentina
  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636636 on ClinicalTrials.gov